Type of ICI and clinical outcome at progression
| Patient | ICI | No of ICI cycles | Site of progression with ICI | Systemic treatment after ICI progression |
| #1 | Nivo | 16 | Me, P, L | Yes |
| #2 | Nivo | 18 | L, Li | Yes |
| #3 | Nivo | 20 | L | Yes |
| #4 | Nivo | 28 | A | Yes |
| #5 | Nivo | 24 | L, B | Yes |
| #6 | Nivo | 42 | CNS | Yes |
| #7 | Pembro | 12 | L | Yes |
| #8 | Nivo | 32 | L, CNS | No |
A, adrenal; B, bone; CL, cervical lymphadenopathies; CNS, central nervous system; ICI, immune checkpoint inhibitor; L, lung; Li, liver; Me, mediastinum; Nivo, nivolumab; P, pleura; Pembro, pembrolizumab.